CoChat

Progress Toward Eliminating Hepatitis A Disease in the United States

Open access
Murphy, Trudy V., Denniston, Maxine M., Hill, Holly A., McDonald, Marian, Klevens, Monina R., Elam-Evans, Laurie D., Nelson, Noele P., Iskander, John, Ward, John D. · 2016 · MMWR Supplements
Cited by 77

The DOI matches its Crossref record.

Abstract

Hepatitis A virus (HAV) disease disproportionately affects adolescents and young adults, American Indian/Alaska Native and Hispanic racial/ethnic groups, and disadvantaged populations.During 1996During -2006, , the Advisory Committee on Immunization Practices (ACIP) made incremental changes in hepatitis A (HepA) vaccination recommendations to increase coverage for children and persons at high risk for HAV infection. This report examines the temporal association of ACIP-recommended HepA vaccination and disparities (on the absolute scale) in cases of HAV disease and on seroprevalence of HAV-related protection (measured as antibody to HAV [anti-HAV]). ACIP-recommended childhood HepA vaccination in the UnitedStates has eliminated most absolute disparities in HAV disease by age, race/ethnicity, and geographic area with relatively modest ≥1-dose and ≥2-dose vaccine coverage.However, the increasing proportion of cases of HAV disease among adults with identified and unidentified sources of exposure underscores the importance of considering new strategies for preventing HAV infection among U.S. adults.For continued progress to be made toward elimination of HAV disease in the United States, additional strategies are needed to prevent HAV infection among an emerging population of susceptible adults.Notably, HAV infection remains endemic in much of the world, contributing to U.S. cases through international travel and the global food economy.MMWR / February 12, 2016 / Vol.65 / No. 1 US Department of Health and Human Services/Centers for Disease Control and PreventionThe epidemiology of acute HAV disease varies worldwide and is in transition in many areas (8-12).In regions where HAV infection has been considered endemic (e.g., Africa, Asia, Central and South America, and Eastern Europe), up to 90% of children are infected by age 10 years (13).Because asymptomatic HAV infection in endemic settings is almost universal during childhood, and is associated with life-long immunity in these settings, illness and deaths from HAV infection are uncommon at any age.As sanitation, access to clean water, and living conditions improve, a decrease occurs in the proportion of persons protected by infection in childhood, HAV disease becomes more frequent among adolescents and adults, and cycles of outbreaks occur as the proportion of the population that is susceptible increases.Because improvements in conditions that foster transmission occur unevenly across communities, disparities in disease incidence can be accentuated by the quality of living conditions, geography, and race/ethnicity of affected populations (3,9,13).In the United States, transition from intermediate to low endemic HAV infection occurred during the second half of the 20th century.During this period, temporal increases in HAV infection and communitywide outbreaks led to cyclic increases in HAV disease approximately every 10-15 years (Figure 1) (5,11,14).Between cyclic increases, the number of reported cases remained ≥21,000 annually (5).When underdiagnosis and underreporting are accounted for, the actual number of cases was estimated to be two to ten times higher (5,15).In 1994, what appeared to be a new cycle of increasing HAV infection began, with 26,796 reported cases (rate: 10.3 cases per 100,000 population) (5).During 1983-1997, the highest case rates were among children aged ≥5 years and young adults, and the lowest case rates were among adults aged ≥40 years.This pattern was still present in 2000 (Figure 2) (3,5,6,14).The 1988-1994 National Health and Nutrition Examination Survey (NHANES) estimated that approximately one third (37.4%; 95% confidence interval [CI]: 35.1%-39.8%) of U.S. adults aged ≥20 years had antibody to HAV (anti-HAV), presumably from past infection.Among the three major racial and ethnic populations evaluated by NHANES, the highest seroprevalence of anti-HAV was among Mexican-American (81.9%; 95% CI: 79.3%-84.4%)and non-Hispanic black adults (50.0%; 95% CI: 47.8%-52.2%);the lowest prevalence was among non-Hispanic white adults (29.0%; 95% CI: 26.9%-31.1%)(17).Cases were unevenly distributed geographically across the United States.During 1987-1997, the highest case rates were in Alaska and the western states (18) (Figure 3).HAV disease also affected racial/ethnic minority populations disproportionately.Rates were well above the national average of 10.3 cases per 100,000 population among American

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.su6501a6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 77

Metadata

Authors
Murphy, T. V., Denniston, M. M., Hill, H. A., McDonald, M., Klevens, M. R., Elam-Evans, L. D., Nelson, N. P., Iskander, J., & Ward, J. D.
Venue
MMWR Supplements
Published
2016-02-12
Volume
65
Issue
1
Pages
29-41
ISSN
  • 2380-8942 (ISSN-L)
  • 2380-8950
OpenAlex
W2276984805
Cited by
77
References
0
FWCI
8.30
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress Toward Eliminating Hepatitis A Disease in the United States. https://app.cochat.ai/papers/10.15585/mmwr.su6501a6
The paper
Murphy, T. V., Denniston, M. M., Hill, H. A., McDonald, M., Klevens, M. R., Elam-Evans, L. D., Nelson, N. P., Iskander, J., & Ward, J. D. (2016). Progress Toward Eliminating Hepatitis A Disease in the United States. MMWR Supplements. https://doi.org/10.15585/mmwr.su6501a6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.